Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > New Strong Buy Stocks for December 23rd by ZACKS EQUITY RSCH
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by Stockcoach1on Dec 28, 2015 12:22pm
128 Views
Post# 24414920

RE:RE:New Strong Buy Stocks for December 23rd by ZACKS EQUITY RSCH

RE:RE:New Strong Buy Stocks for December 23rd by ZACKS EQUITY RSCH
sunshine7 wrote: Saw that but couldn't pull up the reports. Can you post any commentary on CXR if there is one?


Sorry I tried, but Zacks gives error response. There was another link but it really just rehashes it.

https://www.wkrb13.com/markets/974726/concordia-healthcare-cxrx-upgraded-to-strong-buy-at-zacks-investment-research/

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities